Clinical Trials · NCT00894322
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 65
- Start date
- Apr 2009
- Locations
- 1 site, United States
- Primary endpoint
- Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population